Cipher Competitors

Delisted . USA . 
Stock . Cipher Pharmaceuticals
CPHRFDelisted Stock  USD 2.57  0.00  0.00%   
Cipher Pharmaceuticals competes with Bionoid Pharma, Centr Brands Corp, Crescita Therapeutics, Cannara Biotech, and Knight Therapeutics; as well as few others. The company classifies itself under Pharmaceuticals sector and is part of Health Care industry. Analyzing Cipher Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Cipher Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Cipher Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
2.572.572.57
Details
Intrinsic
Valuation
LowRealHigh
2.442.442.83
Details
Naive
Forecast
LowNextHigh
2.442.442.44
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.452.662.87
Details

Cipher Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Cipher Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Cipher and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Cipher Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
HLTRF
+ 0.5
CRRTF
KHTRF
+ 0.49
BINP
ANTCF
+ 0.34
CRRTF
CRRTF
+ 0.3
CTTH
LOWLF
+ 0.27
LOVFF
CRRTF
+ 0.26
CNTRF
  
High negative correlations   
KHTRF
- 0.6
CRRTF
LOWLF
- 0.37
KHTRF
LOVFF
- 0.34
CRRTF
ANTCF
- 0.33
BINP
HLTRF
- 0.32
LOVFF
ANTCF
- 0.3
KHTRF

Risk-Adjusted Indicators

There is a big difference between Cipher OTC Stock performing well and Cipher Pharmaceuticals OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cipher Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BINP  5.64 (0.55) 0.00 (0.12) 0.00 
 0.00 
 25.00 
(33.33)
 95.00 
CNTRF  24.52  7.82  0.24  0.60  12.32 
(205.96)
 80.00 
(12.50)
 547.14 
CTTH  8.03  1.63  0.10  6.81  9.80 
(17.46)
 12.00 
(14.29)
 199.35 
ABTI  7.65  1.24  0.03 (1.86) 11.67 
(41.99)
 25.00 
(13.58)
 171.75 
CRRTF  30.76  15.87  0.00 (6.65) 0.00 
 0.00 
 0.00 
 0.00 
 1,007 
LOVFF  2.54  0.28  0.00 (0.10) 4.38 
(7.77)
 8.51 
(6.90)
 36.67 
KHTRF  0.73 (0.06) 0.00  0.21  0.00 
 0.00 
 1.88 
(2.12)
 14.70 
LOWLF  22.51  3.90  0.16  3.35  20.45 
(34.88)
 60.00 
(33.33)
 124.75 
ANTCF  25.40  8.82  0.00  1.61  0.00 
 0.00 
 76.99 
(48.53)
 451.80 
HLTRF  1.55  0.12  0.01  0.28  2.65 
(5.09)
 6.75 
(4.20)
 23.98 
All Fundamental Data

Cipher Pharmaceuticals Competitive Analysis

The better you understand Cipher Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Cipher Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Cipher Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CPHRF BINP CNTRF CTTH ABTI CRRTF LOVFF KHTRF LOWLF ANTCF
 0.00 
 2.57 
Cipher
 45.00 
 0.11 
Bionoid
 33.33 
 0.12 
Centr
 8.95 
 0.06 
CTT
 25.00 
 0.01 
Alterola
 0.00 
 0.45 
Crescita
 3.85 
 0.54 
Cannara
 1.84 
 3.73 
Knight
 13.33 
 0.02 
Lowell
 84.21 
 0.01 
Aion
Market Volatility
(90 Days Market Risk)
Very steady
Out of control
Out of control
Out of control
Out of control
Out of control
Out of control
Slightly risky
Out of control
Out of control
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Good
Modest
Insignificant
OK
Weak
Very Weak
OK
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Quite High
Above Average
Quite High
Average
Below Average
Low
Low
Average
Quite High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Current Ratio
2.51
0.07
7.02
5.01
0.1
3.1
2.13
2.54
2.25
0.15
Net Asset
51.65 M
N/A
5.89 M
186.54 K
12.13 K
28.92 M
125.62 M
991.89 M
137.38 M
150.14 K
Profit Margin
0.45
N/A
N/A
N/A
N/A
0.025
0.0717
-0.0852
-0.48
N/A
EBITDA
11.85 M
(385.71 K)
(5.28 M)
N/A
(6.47 M)
606 K
8.14 M
58.22 M
(15.74 M)
(3.68 M)
Operating Margin
0.57
-4.22
-4.85
N/A
N/A
0.0403
0.15
-0.0819
-0.38
N/A
Current Valuation
46.13 M
3.81 M
20.12 M
18.87 M
68.08 M
3.64 M
94.03 M
354.32 M
75.28 M
1.22 M
Price To Book
1.63
N/A
11.34
10.64
6.29
0.66
1.37
0.69
0.21
5.77
Beta
1.03
-2.12
-0.44
1.14
-6.65
2.08
1.52
0.5
1.97
0.29
Number Of Employees
26
5
4
15
6
2
9
660
201
4
Shares Outstanding
25.12 M
42.28 M
97.65 M
21.32 M
807.05 M
20.4 M
877.48 M
113.96 M
100.61 M
147.3 M
Cash Flow From Operations
13.81 M
(357.62 K)
(5.57 M)
(145.16 K)
44.34 K
(1.6 M)
(6.08 M)
44.62 M
(26.05 M)
(1.35 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
507 K
64.5 K
31.63 K
87.62 K
251.18 K
1.71 M
46.19 M
9.27 M
22.9 M
643.8 K
Return On Equity
0.24
N/A
-2.51
-4.49
-1.27
0.0318
0.0434
-0.0266
-0.34
-4.17
Z Score
75.6
N/A
N/A
N/A
N/A
3.6
0.6
28.8
N/A
-78.0
Return On Asset
0.15
-1.64
-0.91
-1.54
-0.67
0.0227
0.0327
-0.0133
-0.0831
-0.96
Number Of Shares Shorted
11.43 K
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Book Value Per Share
1.77
-29.92
0.014
0.035
0.013
0.98
0.077
7.5
0.51
-0.012
Total Asset
51.65 M
N/A
5.89 M
186.54 K
12.13 K
28.92 M
125.62 M
991.89 M
137.38 M
150.14 K
Debt To Equity
0.012
N/A
0.12
0.12
0.023
0.085
0.49
0.046
0.95
0.14
Short Ratio
0.97
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Target Price
5.59
N/A
N/A
N/A
N/A
N/A
N/A
N/A
1.2
N/A
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
N/A
N/A
N/A
N/A
N/A
N/A
12.9
5.1
N/A
Market Capitalization
64.32 M
42.28 M
26.67 M
16.17 M
39.55 M
11.42 M
63.27 M
444.73 M
7.59 M
1.47 M
Price To Earning
15.54
N/A
26.92
-3.0
N/A
490.0
85.0
15.3
N/A
N/A
Price To Sales
3.28
540.76
18.14
N/A
N/A
0.41
1.81
1.67
0.24
N/A
Net Income
7.76 M
(1.62 M)
484.94 K
(1.38 M)
(6.47 M)
(1.1 M)
2.31 M
15.68 M
(24.68 M)
(3.82 M)
Earnings Per Share
0.36
-46.27
0.01
-0.08
-0.008
0.02
0.15
-0.042
-0.21
-0.043
Shares Owned By Insiders
44.12
N/A
31.61
N/A
N/A
7.3
47.54
30.54
39.62
17.68
Revenue
21.94 M
92.26 K
1.85 M
40 K
N/A
16.77 M
35.84 M
243.48 M
53.72 M
N/A
Cash And Equivalents
24.19 M
127
3.86 M
32.12 K
61.54 K
10.5 M
3.88 M
147.08 M
2.75 M
1.85 K
Cash Per Share
0.96
N/A
0.04
N/A
N/A
0.51
N/A
1.28
0.03
N/A
Gross Profit
18.26 M
47.48 K
533.4 K
N/A
N/A
10.01 M
17.33 M
115.41 M
2.48 M
(1.5 K)
Day Typical Price
2.57
0.11
0.12
0.0547
0.005
0.45
0.55
3.73
0.0163
0.0105
Accumulation Distribution
N/A
N/A
N/A
0.25
N/A
N/A
0.1
N/A
0.12
N/A
Market Facilitation Index
N/A
N/A
N/A
0.0148
N/A
N/A
0.06
N/A
0.002
N/A
Daily Balance Of Power
0.0
(9,223,372,036,855)
(9,223,372,036,855)
(0.39)
9.2 T
0.0
0.3333
(9,223,372,036,855)
1.0
9.2 T
Period Momentum Indicator
N/A
(0.09)
(0.06)
(0.01)
0.001
N/A
0.02
(0.07)
0.002
0.0048
Rate Of Daily Change
1.0
0.55
0.67
0.91
1.25
1.0
1.04
0.98
1.13
1.84
Day Median Price
2.57
0.11
0.12
0.053
0.005
0.45
0.55
3.73
0.016
0.0105
Price Action Indicator
N/A
(0.04)
(0.03)
0.0022
5.0E-4
N/A
N/A
(0.04)
0.002
0.0024
Relative Strength Index
47.49
34.58
48.93
45.18
44.57
93.7
58.68
36.55
50.67
49.57
Coefficient Of Variation
N/A
(5,405)
678.26
1483.72
1796.32
801.55
4197.46
(1,131)
727.62
623.1
Mean Deviation
N/A
5.64
24.52
8.03
7.65
30.76
2.54
0.7287
22.51
25.4
Jensen Alpha
N/A
(0.55)
7.82
1.63
1.24
15.87
0.2781
(0.06)
3.9
8.82
Total Risk Alpha
N/A
(2.57)
(0.68)
(2.24)
(2.15)
(4.10)
(0.78)
(0.40)
(0.60)
0.1672
Sortino Ratio
N/A
N/A
0.2424
0.0951
0.0263
N/A
6.0E-4
N/A
0.1558
N/A
Downside Variance
N/A
N/A
1590.49
260.54
1565.39
N/A
148.98
N/A
633.41
N/A
Standard Deviation
N/A
14.54
66.44
24.72
21.03
125.01
5.77
1.57
29.48
59.46
Kurtosis
N/A
7.7
42.41
45.61
20.39
63.99
6.76
14.15
0.3607
25.28
Potential Upside
N/A
25.0
80.0
12.0
25.0
N/A
8.51
1.88
60.0
76.99
Treynor Ratio
N/A
(0.12)
0.5981
6.81
(1.86)
(6.65)
(0.10)
0.213
3.35
1.61
Maximum Drawdown
N/A
95.0
547.14
199.35
171.75
1006.52
36.67
14.7
124.75
451.8
Variance
N/A
211.54
4414.73
611.13
442.24
15626.95
33.32
2.48
868.86
3535.2
Market Risk Adjusted Performance
N/A
(0.11)
0.6081
6.82
(1.85)
(6.64)
(0.09)
0.223
3.36
1.62
Risk Adjusted Performance
N/A
(0)
0.1226
0.0612
0.0522
0.1053
0.0269
(0.06)
0.1148
0.1326
Skewness
N/A
(0.90)
6.11
6.0
2.89
8.0
0.1402
(0.20)
0.5594
4.55
Semi Deviation
N/A
N/A
12.32
9.8
11.67
N/A
4.38
N/A
20.45
N/A
Information Ratio
N/A
(0.03)
0.1455
0.0621
0.0495
0.1237
0.0012
(0.17)
0.133
0.1583
Value At Risk
N/A
(33.33)
(12.50)
(14.29)
(13.58)
N/A
(6.90)
(2.12)
(33.33)
(48.53)
Expected Short fall
N/A
N/A
(205.96)
(17.46)
(41.99)
N/A
(7.77)
N/A
(34.88)
N/A
Downside Deviation
N/A
N/A
39.88
16.14
39.57
N/A
12.21
N/A
25.17
N/A
Semi Variance
N/A
N/A
151.78
96.09
136.12
N/A
19.17
N/A
418.12
N/A

Cipher Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Cipher Pharmaceuticals Competition

Cipher Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Cipher Pharmaceuticals in relation to its competition. Cipher Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Cipher Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Cipher Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Cipher Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Cipher Pharmaceuticals position

In addition to having Cipher Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Precious Metals Funds Thematic Idea Now

Precious Metals Funds
Precious Metals Funds Theme
Funds or Etfs that invest in entities that are involved in mining, processing or dealing of precious metals. The Precious Metals Funds theme has 35 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Consideration for investing in Cipher OTC Stock

If you are still planning to invest in Cipher Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cipher Pharmaceuticals' history and understand the potential risks before investing.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY